News
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire
Pfizer to Acquire Biohaven Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire
Quidel Reports First Quarter 2022 Financial Results
Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today financial results for the first
Pfizer Reports First-Quarter 2022 Results
Pfizer Inc. (NYSE: PFE) reported strong financial results for first-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance
Pfizer Reports First-Quarter 2022 Results
Pfizer Inc. (NYSE: PFE) reported strong financial results for first-quarter 2022 and updated certain components of 2022 financial guidance(4). Pfizer reaffirmed its previous 2022 revenue guidance
Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time
DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time). The
Dexcom Updates First Quarter 2022 Conference Call for April 28, 2022 at 5:30 p.m. Eastern Time
DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time). The
Dexcom Reports First Quarter 2022 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2022.
First Quarter 2022 Financial Highlights:
-
Revenue grew 25% versus the same
Dexcom Reports First Quarter 2022 Financial Results
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2022.
First Quarter 2022 Financial Highlights:
-
Revenue grew 25% versus the same
Pfizer Declares Second-Quarter 2022 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 second-quarter 2022 dividend on the company’s common stock, payable June 10, 2022, to holders of the Common
Pfizer Declares Second-Quarter 2022 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.40 second-quarter 2022 dividend on the company’s common stock, payable June 10, 2022, to holders of the Common
DexCom präsentiert auf der internationalen ATTD-Konferenz sein erweitertes CGM-Portfolio, das Menschen mit Diabetes mehr Wahlmöglichkeiten bietet
DexCom, Inc. (Nasdaq: DXCM), der Weltmarktführer im Bereich des kontinuierlichen Glukosemonitoring für Diabetespatienten, wird auf der 15. International Conference on Advanced Technologies and
DexCom präsentiert auf der internationalen ATTD-Konferenz sein erweitertes CGM-Portfolio, das Menschen mit Diabetes mehr Wahlmöglichkeiten bietet
DexCom, Inc. (Nasdaq: DXCM), der Weltmarktführer im Bereich des kontinuierlichen Glukosemonitoring für Diabetespatienten, wird auf der 15. International Conference on Advanced Technologies and
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant)
Pfizer and Biohaven’s VYDURA® (Rimegepant) Granted First Ever Marketing Authorization by European Commission for Both Acute Treatment of Migraine and Prophylaxis of Episodic Migraine
Pfizer Inc. (NYSE: PFE) and Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the European Commission (EC) has granted marketing authorization for VYDURA® (rimegepant)
Agilent to Announce Second-Quarter Fiscal Year 2022 Financial Results May 24
Agilent Technologies Inc. (NYSE: A) today announced that it will release financial results for the second quarter of fiscal year 2022 after the stock market closes on Tuesday, May 24. The company
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate
Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. (NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate
DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People With Diabetes
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous
DexCom Showcases Expanded CGM Portfolio at International ATTD Conference, Offering More Choice to People With Diabetes
DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, will showcase for the first time its new global portfolio of real-time continuous
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2022 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April
Pfizer Invites Shareholders to Attend Virtual-Only 2022 Annual Meeting of Shareholders on April 28
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2022 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April
Agilent Joins the National Institute for Innovation in Manufacturing to Advance Biomanufacturing
Agilent Technologies Inc. (NYSE: A) announced that it has joined the National Institute for Innovation in Manufacturing to Advance Biomanufacturing (NIIMBL). Membership in NIIMBL demonstrates
Humana’s Impact Report Focuses on Building Trust and Transparency in Journey to Health Equity
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, released its 2021 Impact Report, which highlights the company’s continued commitment to its Environment
Pfizer and BioNTech Announce Data Demonstrating High Immune Response Following a Booster Dose of their COVID-19 Vaccine in Children 5 Through 11 Years of Age
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster